Saba Capital Management’s Humacyte HUMA Stock Holding History

Saba Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-55,100	Closed	-$553K	–	447
2020 Q4	$553K	Buy	+55,100	New	+$546K	0.02%	132

Other funds holding HUMA

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Saba Capital Management's HUMA Position: Q1 2021 in Review

Saba Capital Management sold out of Humacyte (HUMA) in Q1 2021, closing a stake of 55,100 shares — an estimated $553K sold.

Saba Capital Management first reported a position in HUMA in Q4 2020 and held it in 1 quarter. The position peaked at $553K in Q4 2020. 23 funds tracked by Wall St. Rank hold HUMA as of Q1 2021.

Saba Capital Management reported no remaining Humacyte position as of Q1 2021 after selling out during the quarter.
Saba Capital Management sold 55,100 Humacyte shares in Q1 2021, an estimated $553K.
Saba Capital Management first reported a position in Humacyte in Q4 2020 and held it in 1 quarter.
Saba Capital Management's Humacyte position peaked at $553K in Q4 2020.
23 funds tracked by Wall St. Rank held Humacyte as of Q1 2021.

Based on Saba Capital Management's 13F filing for Q1 2021, filed 17 May 2021.